X Leleu: Honoraria: AbbVie, Amgen, BMS, Janssen-Cilag, Novartis, Roche, Sanofi, Takeda, Pfizer; Non-financial support: Takeda. HC Lee: Consultancy: BMS, Celgene, Genentech, Karyopharm, Legend Biotech, GSK, Sanofi, Oncopeptides, Pfizer, Takeda, Allogene Therapeutics, Janssen Pharmaceutical; Research funding: BMS, Janssen, GSK, Takeda, Regeneron, Amgen. JA Zonder: Consultancy: Prothena, BMS, Takeda, Janssen, Regeneron, Research funding: BMS, Janssen; Member of board of directors/advisory committees: Takeda, BMS. MM: Honoraria: Takeda, Janssen, GSK, Sanofi, BMS/Celgene; Travel, accommodation, and research funding: Takeda, Janssen. K Ramasamy: Honoraria and member of board of directors/advisory committees: Amgen, Janssen, Takeda, BMS/Celgene, GSK, Oncopeptides, Adaptive Biotech, Karyopharm, Pfizer, Sanofi; Research funding: Amgen, Janssen, Takeda, BMS/Celgene, GSK; Travel and conference registration: Amgen, Janssen, Takeda, BMS/Celgene. C Hulin: Honoraria: Janssen, BMS/Celgene, Sanofi, Takeda, AbbVie. J Silar, M Kuhn: None. KRen, NB-E, DC, DMS: Employee: Takeda (D Cherepanov and DM Stull also currently hold equity in Takeda). E Terpos: Research funding, honoraria, and consultancy: Amgen, BMS, GSK, Janssen-Cilag, Takeda, Sanofi; Honoraria only: Eusa Pharma, Novartis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.